Medullary cystic kidney disease

WikiDoc Resources for Medullary cystic kidney disease
Articles
Most recent articles on Medullary cystic kidney disease Most cited articles on Medullary cystic kidney disease Review articles on Medullary cystic kidney disease Articles on Medullary cystic kidney disease in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Medullary cystic kidney disease Images of Medullary cystic kidney disease Photos of Medullary cystic kidney disease Podcasts & MP3s on Medullary cystic kidney disease Videos on Medullary cystic kidney disease
Evidence Based Medicine
Cochrane Collaboration on Medullary cystic kidney disease Bandolier on Medullary cystic kidney disease TRIP on Medullary cystic kidney disease
Clinical Trials
Ongoing Trials on Medullary cystic kidney disease at Clinical Trials.gov Trial results on Medullary cystic kidney disease Clinical Trials on Medullary cystic kidney disease at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Medullary cystic kidney disease NICE Guidance on Medullary cystic kidney disease NHS PRODIGY Guidance FDA on Medullary cystic kidney disease CDC on Medullary cystic kidney disease
Books
Books on Medullary cystic kidney disease
News
Medullary cystic kidney disease in the news Be alerted to news on Medullary cystic kidney disease News trends on Medullary cystic kidney disease
Commentary
Blogs on Medullary cystic kidney disease
Definitions
Definitions of Medullary cystic kidney disease
Patient Resources / Community
Patient resources on Medullary cystic kidney disease Discussion groups on Medullary cystic kidney disease Patient Handouts on Medullary cystic kidney disease Directions to Hospitals Treating Medullary cystic kidney disease Risk calculators and risk factors for Medullary cystic kidney disease
Healthcare Provider Resources
Symptoms of Medullary cystic kidney disease Causes & Risk Factors for Medullary cystic kidney disease Diagnostic studies for Medullary cystic kidney disease Treatment of Medullary cystic kidney disease
Continuing Medical Education (CME)
CME Programs on Medullary cystic kidney disease
International
Medullary cystic kidney disease en Espanol Medullary cystic kidney disease en Francais
Business
Medullary cystic kidney disease in the Marketplace Patents on Medullary cystic kidney disease
Experimental / Informatics
List of terms related to Medullary cystic kidney disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

• [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].